KumaMax: Winner of C4C Recognition as a Novel Oral Therapeutic for Celiac Disease

 

Dr. Ingrid Swanson Pultz wins first prize at C4C's 2013 Innovators Recognition Event

Dr. Ingrid Swanson Pultz, a Translational Investigator at the Institute for Protein Design won first prize at the UW Center for Commercialization 2013 Innovator Recognition Event, for KumaMax, an enzyme designed in the Baker lab to efficiently break down gluten within the acidic environment of the stomach, before it can reach the small intestine where intact gluten may otherwise cause an inflammatory reaction in people who suffer from celiac disease.  Learn more at this link.

Share via
Copy link